Biotech in a Bull Market, Not a Bubble: StockTwits

NEW YORK (TheStreet) -- The biotech sector is due for a bounce, say investors on Instead of setting up for continued contraction Monday, many cashtaggers on the leading investing social network maintained that last week's sell-off created buying opportunities. And they refuted arguments that biotech valuations had inflated to bubble proportions and were now, rightly, losing hot air.

You buy pullback not sell it in a bull market. Forget all the nice "intelligent" stories out there. No one can predict the top $SPY $IBB

-- leopardtrader (@leopardtrader) Apr. 6 at 09:35 AM

The Nasdaq Biotechnology ETF (IBB) is down 7% since April 1. But sentiment on the ETF is still 50% bullish, according to StockTwits' analytics, despite the dismal performance. ProShares UltraShort Nasdaq Biotech ETF (BIS), for comparison, has 56% bearish sentiment.

$BIB & $IBB charts similar both lost TL support & nearing 200day ma. bounce coming imo $bis

-- Alto Ster (@Good2go) Apr. 5 at 08:24 PM

The negative opinion on the short biotech ETF is attention-grabbing, given recent gains. The BIS ETF, which aims to return double the loss of the Nasdaq's biotech holdings, is up 14%-plus since April 1. Typically, asset gains increase bullish sentiment.

Some investors believe upcoming medical conferences will change the tide for the sector. They argue that news announced at the American Association for Cancer Research's annual meeting (held April 5 to 9) and at the International Liver Congress (held April 9 to 13 in London) will attract investors back to beaten-down names.

If you liked this article you might like

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

Indices Don't Have Much in Common

Trader's Daily Notebook: 3 ETFs With Healthy Setups

Trader's Daily Notebook: Keeping a Short Leash